CDK12 and breast carcinoma: Further supporting the therapeutic actionability of the folate one-carbon metabolism for CDK12-overexpressing breast cancers, in vivo MTX administration delayed tumorigenicity and reduced lung metastasis by more than 50% in CDK12-KI/PyMT mice, with no effects observed in WT/PyMT mice (Fig. 7a, b).